Biology:Neuropeptide Y receptor

From HandWiki
Revision as of 00:36, 13 February 2024 by MedAI (talk | contribs) (fix)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Protein family
neuropeptide Y receptor Y1
Identifiers
SymbolNPY1R
Alt. symbolsNPYR
NCBI gene4886
HGNC7956
OMIM162641
RefSeqNM_000909
UniProtP25929
Other data
LocusChr. 4 q31.3-q32
neuropeptide Y receptor Y2
Identifiers
SymbolNPY2R
NCBI gene4887
HGNC7957
OMIM162642
RefSeqNM_000910
UniProtP49146
Other data
LocusChr. 4 q31
pancreatic polypeptide receptor 1
Identifiers
SymbolPPYR1
Alt. symbolsNPY4R, Y4, PP1
NCBI gene5540
HGNC9329
OMIM601790
RefSeqNM_005972
UniProtP50391
Other data
LocusChr. 10 q11.2
neuropeptide Y receptor Y5
Identifiers
SymbolNPY5R
NCBI gene4889
HGNC7958
OMIM602001
RefSeqNM_006174
UniProtQ15761
Other data
LocusChr. 4 q31-q32

Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]

Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.

Only the crystal structure of Y1 in complex with two antagonist is available.[8]

Types

There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[9] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[10][11][12]

Antagonists

References

  1. "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. March 1998. PMID 9549761. http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9549761. 
  2. Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373. 
  3. Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800. 
  4. "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. 2007. doi:10.2174/156802607782341037. PMID 17979774. 
  5. "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. November 2006. doi:10.2174/157488906778773689. PMID 18221213. 
  6. "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. 2007. doi:10.2174/156802607782340966. PMID 17979780. 
  7. "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. September 2008. doi:10.1016/j.nut.2008.06.025. PMID 18725086. 
  8. "1 receptor". Nature 556 (7702): 520–524. April 2018. doi:10.1038/s41586-018-0046-x. PMID 29670288. 
  9. "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. 2004. doi:10.1016/j.npep.2004.06.002. PMID 15337367. 
  10. "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. October 2007. doi:10.1210/er.2007-0003. PMID 17785427. 
  11. MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781. 
  12. "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. 2007. doi:10.2174/156802607782340957. PMID 17979782. 

External links